Group Sequential and Adaptive Methods for Clinical Trials Group Sequential and Adaptive Methods for Clinical Trials
Chapman & Hall/CRC Biostatistics Series

Group Sequential and Adaptive Methods for Clinical Trials

    • $72.99
    • $72.99

Publisher Description

In clinical trials, monitoring accumulating data at regular intervals is essential for balancing ethical and financial considerations against scientific rigor. This comprehensive second edition reflects the remarkable evolution in adaptive clinical trial methodology over the past two decades. Since publication of the first edition, these approaches have transformed from theoretical concepts to widely accepted practices, now endorsed by regulatory authorities, including formal FDA guidance.

Features
Eleven entirely new chapters, including optimal design construction, delayed "pipeline" data accommodation, and multiple comparison procedures Eight dedicated chapters on adaptive methods including sample size re-assessment, seamless Phase II/III trials, multi-arm multi-stage trials, and enrichment designs Exact methods for binary and Poisson data with applications to vaccine trials Expanded discussion of binding versus non-binding futility boundaries for enhanced decision-making A chapter with a thoroughly updated review of Bayesian approaches to sequential trial design and analysis Incorporates response-adaptive treatment assignment in group sequential designs Practical computational methods and software guidance for implementing the techniques
This definitive resource serves statisticians, clinical researchers, pharmaceutical scientists, and regulatory professionals involved in clinical trial design and analysis. The text balances theoretical foundations with practical implementation guidance, making it invaluable for both experienced practitioners and those new to adaptive trial methodology. With twice the content of the first edition, Group Sequential and Adaptive Methods for Clinical Trials, Second Edition provides the comprehensive understanding needed to design more efficient, ethical, and scientifically rigorous clinical trials, ultimately accelerating the delivery of effective treatments to patients.

GENRE
Science & Nature
RELEASED
2025
December 8
LANGUAGE
EN
English
LENGTH
648
Pages
PUBLISHER
CRC Press
SELLER
Taylor & Francis Group
SIZE
22.1
MB
Golden Boys Golden Boys
2012
Pinstripe Quotes Pinstripe Quotes
2013
Real-World Evidence in Drug Development and Evaluation Real-World Evidence in Drug Development and Evaluation
2021
Medical Risk Prediction Models Medical Risk Prediction Models
2021
Biomarker Analysis in Clinical Trials with R Biomarker Analysis in Clinical Trials with R
2020
Biosimilar Clinical Development: Scientific Considerations and New Methodologies Biosimilar Clinical Development: Scientific Considerations and New Methodologies
2016
Innovative Methods for Rare Disease Drug Development Innovative Methods for Rare Disease Drug Development
2020
Statistical Design, Monitoring, and Analysis of Clinical Trials Statistical Design, Monitoring, and Analysis of Clinical Trials
2021